logged in.
news
Latest News
Posted 28-Nov-2018
OCALIVA obeticholic acid tablets (5 mg and 10 mg) are now TGA Registered ProductsPosted 17-Oct-2018
Emerge Health Change of Office AddressPosted 10-May-2018
Emerge Health signs marketing and distribution agreement with DiurnalPosted 19-Feb-2018
Media Release: SATIVEX® (nabiximols) now available in Australia for MS spasticityPosted 01-Feb-2018
Transfer of Sponsorship of CLEVIPREX® from The Medicines Company Australia Pty Ltd
EMERGE HEALTH PTY LTD a specialty medicines company, today announced that it will be taking over the Sponsorship of CLEVIPREX® (clevidipine) effective as of the 6th of December 2016.
Following the Transfer of Sponsorship there will be no change to the availability of CLEVIPREX for your hospital or patients. All hospital pharmacies will be able to order Cleviprex through Emerge Health.
Please note, The Medicines Company contact details will continue to appear on the CLEVIPREX packaging until current stocks are exhausted.
From the 6th of December, all orders, medical and product enquiries and adverse event reports concerning CLEVIPREX should be directed to Emerge Health on:
Direct: (03) 9077 4486
Fax: (03) 8672 0793
E-mail: customerservice@emergehealth.com.au
Mail: Emerge
Health
Suite 3, Level 1, 2 Theatre Place
Canterbury VIC 3126 Australia
In case of emergency please call (03) 9939 1482.
If you have any questions regarding this change, please contact Emerge Health on (03) 9077 4486.